Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1468-1472

  Feine, Ulrich ^a   Lietzenmayer, Roland ^a   Hanke, Jacek P ^a   Held, Jürgen ^a   Wöhrle, Helmut ^a   Müller Schauenburg, Wolfgang ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

fluorine 18 FDG PET; iodine 131; thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA; ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029779869     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ng TF, SC. Hoffenberg R, Maisey MN, Black E. Serum thyroglobulin concentrations and whole-body radiodine scan in follow-up of differentiated thyroid cancer after thyroid ablation. Br Med J 1979;2:298-300.
2. 201TI for detection of recurrent metastatic differentiated thyroid cancer [Abstract]. J Nucl Med 1995; 36(suppl):203P.
3. Strauss L, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
4. Börner AR, Voth E, Schicha H. Fluorine-18-FDG PKT in patients with immunogenic hyperthyroidism prior to radioiodine therapy. Nuklearmedizin 1994;33:A81.
5. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987;28:910-914.
6. 18FDG-PET in primary and metastatic thyroid cancer. J Nucl Med 1995;36(suppl):196P.
7. 18FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164-167.
8. Bilger K. Effects of object size and nonuniformity resolution on quantitative measurements with a new PET Scanner. PhD thesis, University of Tuebingen; 1995.
9. Feine U, Lietzenmayer R, Müller-Schauenburg W, et al. Fluorine-18-FDG whole-body PET in differentiated thyroid carcinoma. 1995;34:127-134.
10. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728-735.
11. Voth E, Börner AR, Theissen P, Schicha H. Positron emission tomography (PET) in benign thyroid diseases. Exp Clin Endocrinol 1994;102:71-74.
12. 18F-fluoro-2-deoxyglucose and positron emission tomography. Exp Clin Endocrinol 1994;102:51-54.
13. 18F-fluoro-2-deoxy-d-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Melab 1993;77:1090-1094.
14. Castillo LA, Yen PJ, Leeper RD, Benia RS. Bone scans in bone metastases from functioning thyroid carcinoma. Clin Nucl Med 1980;5:201-206.
15. 18F-fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-371.